Table 1.
Participant disposition
| n (%) | |
|---|---|
| All enrolled people with CF | 129 |
| Completed study | 124 (96.1) |
| Discontinued from study | 5 (3.9) |
| Reason for discontinuation from study | |
| Physician decisiona | 3 (2.3) |
| Otherb | 2 (1.6) |
| Started ivacaftor treatment at or after enrollment | 9 (7.0) |
| Started ivacaftor 0 to 3 months after enrolling | 9 (7.0) |
| Enrolled in study after starting ivacaftor treatment | 120 (93.0) |
| Enrolled > 0 to 6 months after starting ivacaftor | 12 (9.3) |
| Enrolled > 6 to 12 months after starting ivacaftor | 14 (10.9) |
| Enrolled > 12 to 24 months after starting ivacaftor | 31 (24.0) |
| Enrolled > 24 to 36 months after starting ivacaftor | 7 (5.4) |
| Enrolled > 36 to 48 months after starting ivacaftor | 15 (11.6) |
| Enrolled > 48 months after starting ivacaftor | 41 (31.8) |
| Months of ivacaftor treatment completed (months) | |
| ≥ 12 | 129 (100.0) |
| ≥ 24 | 123 (95.3) |
| ≥ 36 | 99 (76.7) |
| ≥ 48 | 68 (52.7) |
CF cystic fibrosis
aOne person with CF underwent a bilateral lung transplantation. Two people with CF were included in a clinical study of cystic fibrosis transmembrane conductance regulator modulators
bOne person with CF discontinued after moving to a different city. One person with CF was lost to follow-up